1 week Ago By Defense World Staff
Psychemedics Co. ( NASDAQ:PMD – Get Free Report )’s share price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.
34 and traded as high as $2.77. Psychemedics shares last traded at $2.
67, with a volume of 113,600 shares changing hands. Psychemedics Price Performance The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.
59 and a current ratio of 1.59. The company has a market cap of $15.
73 million, a PE ratio of -5.24 and a beta of 0.65.
The company’s 50-day simple moving average is $2.47 and its 200 day simple moving average is $2.34.
Insider Buying and Selling at Psychemedics In other news, major shareholder Powell Anderson Capital Partne acquired 60,000 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was acquired at an average cost of $1.97 per share, with a total value of $118,200.
00. Following the transaction, the insider now owns 604,556 shares in the company, valued at approximately $1,190,975.32.
This trade represents a 11.02 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink .
Also, Director Peter Kamin acquired 1,409,712 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $2.35 per share, with a total value of $3,312,823.
20. Following the completion of the transaction, the director now owns 1,820,418 shares in the company, valued at approximately $4,277,982.30.
The trade was a 343.24 % increase in their position. The disclosure for this purchase can be found here .
Insiders acquired 1,552,185 shares of company stock valued at $3,650,628 in the last 90 days. Company insiders own 13.96% of the company’s stock.
About Psychemedics Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. See Also Five stocks we like better than Psychemedics What is the Dogs of the Dow Strategy? Overview and Examples Work and Play: Investing in the Rise of Bleisure Travel How to Calculate Stock Profit Top Dividend Stocks to Buy Now as Bond Yields Could Lower Are Penny Stocks a Good Fit for Your Portfolio? SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.
com's FREE daily email newsletter ..
